Essential Tremor
Essential tremor (ET) is one of the most common movement disorders, with a global prevalence of roughly 0.9%. It is increasingly frequent in older age groups (Ferreira et al., 2019; Wong et al., 2020). It is defined as an isolated, bilateral upper extremity action tremor of at least three years’ duration. This can occur with or without tremor in other body regions and without additional neurological signs such as parkinsonism, dystonia, or cerebellar ataxia (Wong et al., 2020). Tremor typically involves the hands but may extend to the head, voice, jaw, and lower limbs. This leads to difficulties in writing, drinking, eating, fine motor tasks, and sometimes gait.
Although ET is not life-threatening, it is often progressive. Longitudinal data suggest a 2–5% per-year increase in arm tremor amplitude over time (Wong et al., 2020). Many patients adapt, but a substantial subset develop socially embarrassing and functionally disabling tremor. This interferes with employment and independence (Dallapiazza et al., 2019). First-line pharmacologic therapy consists mainly of propranolol and primidone. These treatments yield mean tremor amplitude reductions of about 55–60%, and up to approximately 70% when combined (Wong et al., 2020; Martinez-Nunez et al., 2024). Nevertheless, only about half of patients achieve satisfactory functional benefit. A large proportion discontinue medication due to limited efficacy or side effects. This treatment gap underlies the need for neuromodulation strategies such as deep brain stimulation (DBS) in carefully selected, medication-refractory ET.
Why Deep Brain Stimulation for Essential Tremor? Understanding Essential Tremor: Symptoms and Diagnosis
Deep brain stimulation is an established surgical option for patients with medication-refractory, functionally disabling ET. This typically occurs after failure or intolerance of adequate trials of propranolol, primidone, and other guideline-supported agents (Ferreira et al., 2019; Wong et al., 2020). Up to 50–55% of patients remain significantly symptomatic despite optimized pharmacotherapy. This makes them potential DBS candidates (Martinez-Nunez et al., 2024).
Evidence syntheses consistently position DBS among the most effective interventions for severe ET. In the large Movement Disorder Society evidence-based review, unilateral thalamic (VIM) DBS was classified as “possibly useful” for limb tremor, alongside radiofrequency and MRI-guided focused ultrasound thalamotomy (Ferreira et al., 2019).
Recent evidence is highly supportive of DBS. A 2024 Bayesian network meta-analysis comparing 33 randomized trials found that DBS provided the largest overall reduction in tremor severity among all studied treatments. It ranked first in relative efficacy, outperforming both medications and other interventional procedures (Zhang et al., 2024).
Clinically, VIM DBS offers strong and predictable outcomes. Most patients experience a 53–63% reduction in tremor within the first year after unilateral implantation. In contrast, bilateral DBS—treating both upper limbs—typically achieves 66–78% improvement. Long-term follow-up studies further show that these benefits are generally maintained for more than five years. The majority of patients continue to experience meaningful tremor control. A small subset may show mild habituation over time, but overall tremor suppression and patient satisfaction remain high (Wong et al., 2020; Børretzen et al., 2014).
Importantly, DBS is adjustable and reversible. This allows postoperative programming to optimize tremor control while minimizing stimulation-induced dysarthria, ataxia, and gait disturbance (Chandra et al., 2022; Martinez-Nunez et al., 2024).
For a neuromodulation-focused practice, DBS therefore occupies a central role as the preferred bilateral, non-ablative intervention in ET patients whose tremor remains disabling despite best medical therapy, particularly when long-term quality of life and flexibility of treatment are prioritized over single-session lesioning approaches.
DBS Procedure & Targets in Essential Tremor
Deep brain stimulation (DBS) for essential tremor is usually done by a team that includes a movement-disorder neurologist, a functional neurosurgeon, and DBS programmers. Before surgery, doctors confirm that the tremor is truly essential tremor and not another condition such as Parkinson’s disease or dystonia. They also check that medications have already been tried without enough benefit, perform a brain MRI, and evaluate memory and mood to make sure DBS is safe (Wong et al., 2020; Chandra et al., 2022).
The most common DBS target is the ventral intermediate nucleus (VIM) of the thalamus. This area is part of the brain’s tremor circuit and receives signals from the cerebellum through the dentato-rubro-thalamic tract (DRTT). Because of its location, stimulating the VIM can effectively interrupt the abnormal tremor signals (Iorio-Morin et al., 2020).
Some centers also use the posterior subthalamic area (PSA) or the caudal zona incerta (cZi). These targets may sometimes provide strong tremor reduction with lower stimulation settings, but they can also cause more balance or speech problems if the stimulation spreads too far (Wong et al., 2020; Martinez-Nunez et al., 2024).
During surgery, the electrode is placed using MRI/CT images and sometimes microelectrode testing to confirm the correct spot. The lead is then connected to a small battery (IPG) placed under the skin of the chest (Chandra et al., 2022). Modern DBS systems often use directional leads, which allow doctors to steer the current more precisely. This helps improve tremor control while reducing side effects like tingling or slurred speech (Wong et al., 2020; Iorio-Morin et al., 2020).
Programming starts a few weeks after surgery and continues over several follow-up visits. Doctors adjust the frequency (usually around 130 Hz), pulse width, and amplitude to find the best balance between tremor control and comfort. Directional stimulation and newer programming algorithms have made this process even safer and more effective (Chandra et al., 2022; Martinez-Nunez et al., 2024).
Clinical Outcomes & Long-Term Efficacy of DBS in Essential Tremor
Deep brain stimulation (DBS) provides one of the most potent and durable therapeutic effects for medication-refractory essential tremor (ET), consistently outperforming pharmacologic therapy and most ablative procedures. Across decades of observational series, controlled studies and meta-analyses, VIM–PSA–cZi neuromodulation has demonstrated robust tremor reduction, meaningful functional improvement and sustained quality-of-life gains in appropriately selected patients.
Short- and Mid-Term Outcomes
Deep brain stimulation provides strong tremor control early after surgery. Most studies show that unilateral VIM DBS reduces tremor by about 53–63% within the first year, while bilateral DBS improves tremor by about 66–78%, since both upper limbs are treated (Dallapiazza et al., 2019). These improvements are usually measured with standardized scales such as the Fahn–Tolosa–Marin Tremor Rating Scale. Many patients also notice improvement early, sometimes within the first few programming sessions during the first month.
A large 2024 network meta-analysis that compared 33 randomized trials confirmed that DBS currently ranks as the most effective tremor treatment available. DBS produced the largest reduction in tremor severity compared with placebo and outperformed all medications and other procedures. In this analysis, DBS also had the highest overall efficacy ranking (SUCRA 0.97) among 25 different treatment options (Zhang et al., 2024).
Target-Specific Results
The VIM remains the most common used and best-studied target. However, research shows that stimulating the posterior subthalamic area (PSA) or caudal zona incerta (cZi) can sometimes produce equal or even stronger tremor suppression, especially in patients with severe proximal or intention tremor. The downside is that PSA and cZi DBS may have a smaller safety margin, meaning that small changes in stimulation can cause speech or balance problems (Wong et al., 2020; Iorio-Morin et al., 2020).
Newer directional leads help reduce these side effects by allowing the clinician to steer current more precisely.
Durability of Tremor Control
One of the major strengths of DBS is its long-term durability. Several long-term studies show that most patients continue to have strong tremor reduction for 5–10 years or more. Some people experience mild “habituation,” meaning the tremor slowly becomes a bit stronger again over time. However, the majority still report meaningful benefits.
In a 6-year follow-up from Norway, patients rated their tremor improvement as 8.5/10 right after surgery and 7.4/10 at long-term follow-up (Børretzen et al., 2014). Despite this small decline, patients reported very high overall satisfaction (median 10/10) many years after surgery.
Importantly, DBS does not seem to increase mortality. The same long-term study reported a standardized mortality ratio of 1.3, which is similar to the general population. Only one suicide occurred, and the numbers were too small to link it directly to DBS.
Quality of Life & Functional Outcomes
Functional gains parallel tremor reduction. Across studies, activities such as handwriting, drinking, and eating improve significantly after DBS. Quality-of-life improvements range from 57% to 82% in validated measures (Dallapiazza et al., 2019). Bilateral stimulation provides the greatest improvements in tasks requiring bimanual coordination and fine motor precision.
Summary
DBS offers a unique therapeutic combination:
large-magnitude tremor suppression
bilateral titratable benefit,
long-term durability, and
reversibility with programmable flexibility.
For neuromodulation centers, these outcomes firmly establish DBS as the cornerstone therapy for disabling, refractory essential tremor—superior in efficacy and durability to all existing medical and ablative alternatives.
Side Effects & Safety Profile
DBS is generally safe and well-tolerated, but as with all neuromodulation procedures both surgical and stimulation-induced side effects may occur. Surgical risks are uncommon and include intracranial hemorrhage, infection, lead or hardware malfunction, and wound complications; these events remain rare in modern series and are comparable to other stereotactic procedures (Chandra et al., 2022).
The more frequent concerns arise from stimulation itself, due to current spread to neighboring thalamic and cerebellothalamic pathways. The most commonly reported stimulation-related effects are dysarthria, ataxia, gait imbalance, limb incoordination, paresthesias, and disequilibrium (Martinez-Nunez et al., 2024). These typically improve with parameter adjustment such as lowering amplitude, narrowing pulse width, changing contact configuration, or utilizing directional leads to “steer” current away from sensitive fiber tracts. Because ET itself can present with soft signs resembling these symptoms, careful preoperative documentation of baseline speech and gait is essential.
Long-term DBS safety is favorable. In a 6-year follow-up of VIM DBS, patients reported high satisfaction and sustained benefit, and the overall mortality rate did not exceed that of the general population (Børretzen et al., 2014). While rare cases of habituation and chronic gait disturbance have been described, permanent adverse effects are uncommon especially compared with irreversible ablative procedures.
For modern neuromodulation centers, DBS offers a reversible, adjustable and safe treatment pathway, with side effects that are largely manageable through expert programming and individualized target selection.
DBS vs Other Treatment Options
Management of essential tremor (ET) spans pharmacologic therapy, botulinum toxin injections, and interventional options such as radiofrequency (RF) thalamotomy, Gamma Knife radiosurgery (GKRS), and MR-guided focused ultrasound (MRgFUS). Deep brain stimulation (DBS), however, remains the most versatile and durable option for patients with medication-refractory tremor.
Medication Therapy
First-line agents such as propranolol and primidone typically reduce tremor amplitude by 55–60%, and combination therapy may reach ~70% improvement (Wong et al., 2020). Despite these benefits, only about half of patients achieve meaningful functional relief, and many discontinue due to fatigue, hypotension, cognitive dulling, or intolerance (Ferreira et al., 2019). This ceiling effect often leads patients toward neuromodulation or ablative interventions.
Botulinum Toxin
Botox can be effective for head or voice tremor and for refractory hand tremor, but functional limitations, especially grip weakness, restrict its wider use. It remains an adjunct rather than a definitive therapy.
Ablative Procedures: RF, GKRS, MRgFUS
RF thalamotomy produces strong unilateral tremor reduction (74–90%) but carries higher risks of permanent dysarthria, imbalance, or sensory deficits due to irreversible tissue destruction (Dallapiazza et al., 2019). GKRS offers a noninvasive alternative with moderate improvement (48–63%) but a delayed onset and variable lesion size.
MRgFUS thalamotomy provides promising unilateral tremor suppression (35–75%) with immediate effect and no incisions but is limited by its irreversible lesion, contraindications (e.g., skull density), and difficulty treating both sides safely.
Why DBS Stands Apart
DBS consistently achieves bilateral, adjustable, long-term tremor control, with 53–63% improvement unilaterally and up to 78% bilaterally, while offering reversibility and a wide programmable therapeutic window. Directional leads, current steering, and newer algorithms further enhance safety relative to ablation. Importantly, DBS avoids the permanent neurologic complications associated with bilateral lesions, enabling tailored therapy across disease progression.
In summary, for patients requiring sustained, bilateral, customizable tremor suppression, DBS offers the most comprehensive risk–benefit balance among current treatment options. This makes it the preferred neuromodulation strategy in modern clinical practice.
Advances in Tremor Neuromodulation
The field of tremor neuromodulation has expanded rapidly over the past decade, driven by technological innovation and a deeper understanding of cerebello-thalamo-cortical circuitry. Modern DBS systems now go beyond simple high-frequency stimulation and offer sophisticated tools that enhance precision, safety, and long-term durability of therapy.
Directional (Segmented) Leads
One of the most impactful advances is the introduction of directional DBS leads, which divide the electrode ring into independently activated segments. This allows current steering toward the dentato-rubro-thalamic tract (DRTT) while avoiding pathways associated with dysarthria, ataxia or paresthesias (Wong et al., 2020; Iorio-Morin et al., 2020). Directionality provides a wider therapeutic window and offers meaningful improvements for patients with narrow safety margins at traditional VIM targets.
Adaptive and Sensing-Enabled Systems
New-generation pulse generators incorporate sensing technology capable of recording local field potentials. Although still emerging in ET, adaptive DBS (aDBS) platforms aim to adjust stimulation in real time based on neural biomarkers—potentially reducing habituation, power consumption, and stimulation-induced side effects.
Advanced Targeting & Connectomics
Contemporary imaging methods, including tractography-guided targeting, have strengthened precision placement along the DRTT. This approach refines electrode location beyond atlas-based coordinates and improves outcomes, especially for PSA/cZi stimulation where fiber density is high (Chandra et al., 2022).
Novel Stimulation Paradigms
Investigational paradigms such as burst stimulation, coordinated reset stimulation, and dual-target DBS (e.g., VIM + PSA) are being explored to address tremor habituation and improve control of proximal or midline tremor phenotypes.
Battery & Hardware Improvements
Rechargeable IPGs, enhanced MRI compatibility, and smaller device profiles increase patient comfort and reduce lifetime surgical burden.
Overall, these advances position DBS as a highly customizable, circuit-informed therapy. As neuromodulation technology continues to evolve, ET patients are increasingly benefiting from safer, more durable, and more precise tremor control than ever before.
References
Ferreira JJ, Mestre TA, Lyons KE, et al. MDS Evidence-Based Review of Treatments for Essential Tremor. Movement Disorders. 2019.
Essential Tremor is a condition that significantly impacts the quality of life, and understanding its treatment options is crucial for those affected.
Martinez-Nunez AE, Sarmento FP, Chandra V, et al. Management of essential tremor deep brain stimulation–induced side effects. Frontiers in Human Neuroscience. 2024.
Zhang J, Yan R, Cui Y, et al. Treatment for essential tremor: A systematic review and Bayesian model-based network meta-analysis of randomized controlled trials. EClinicalMedicine. 2024.
Dallapiazza RF, Lee DJ, De Vloo P, et al. Outcomes from stereotactic surgery for essential tremor. Journal of Neurology, Neurosurgery & Psychiatry. 2019.
Iorio-Morin C, Fomenko A, Kalia SK. Deep-brain stimulation for essential tremor and other tremor syndromes: A narrative review of current targets and clinical outcomes. Brain Sciences. 2020.
Chandra V, Hilliard JD, Foote KD. Deep brain stimulation for the treatment of tremor. Journal of the Neurological Sciences. 2022.
Wong JK, Hess CW, Almeida L, et al. Deep brain stimulation in essential tremor: Targets, technology, and a comprehensive review of clinical outcomes. Expert Review of Neurotherapeutics. 2020.
Børretzen MN, Bjerknes S, Sæhle T, et al. Long-term follow-up of thalamic deep brain stimulation for essential tremor: Patient satisfaction and mortality. BMC Neurology. 2014.